1. In Vivo

Pfizer’s Paxlovid And The Murky World Of Rx Drug Communication

 
• By Sarah Karlin-Smith

Pfizer social media announcement that it’s seeking full approval for the oral COVID antiviral raise questions about where the line is on promotion versus other communications, FDA’s ability to regulate pharma on social media, and the unique considerations of promotion under EUAs.

paxlovid under eua
Pfizer created a video to announce Paxlovid’s NDA submission on 30 June • Source: Shutterstock

Pfizer Inc. announced its submission of a new drug application for its COVID-19 antiviral Paxlovid (nirmatrelvir and ritonavir) 30 June with not just the typical company press release, but also with a silent 30-second video posted on Twitter and Facebook that describes its oral treatment as an “important option,” for individuals at risk of progressing to severe COVID-19 illness.

The video raises questions about how companies can communicate about an unapproved product and the unique circumstances of promotion under...

More from COVID-19

More from In Vivo

Strategic Surprises: The Drugs That Rewrote The Forecasts

 
• By Edwin Elmhirst

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 
• By Anabel Costa-Ferreira

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By Barnaby Pickering

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.